Placental stem cells

• US 7,468,276 B2
• Filed: 06/22/2004
• Issued: 12/23/2008
• Est. Priority Date: 12/06/2000
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/874,828
• Publication Number:
  US 20050019908A1
• Time in Patent Office: 1,645 Days
• Field of Search: None
• US Class Current: 435/325
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/90 : Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2509/00 : Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/90 : Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 : General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Claims

1. An isolated human placental stem cell that is OCT-4⁺ and CD34⁻

, wherein OCT-4 is octamer binding protein 4, and wherein said placental stem cell has at least the following characteristics;

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH3⁺, SH4⁺, SSEA3⁻

, and SSEA4⁻

.

5. The isolated human placental stem cell of claims 1, 2 or 3 wherein said cell has the potential to differentiate into a cell of a neural phenotype.

6. The isolated human placental stem cell of claims 1, 2 or 3 wherein said cell has the potential to differentiate into a cell of an osteogenic or chondrogenic phenotype.

7. An isolated cell population comprising the human placental stem cells of claim 1.

17. The isolated placental stem cell of claims 1, 2 or 3, wherein said isolated placental stem cell adheres to tissue culture plastic.

2. An isolated human placental stem cell, wherein said placental stem cell is OCT-4⁺, CD34⁻

, SSEA3⁻

and SSEA4⁻

.

8. An isolated cell population comprising the human placental stem cells of claim 2.

3. An isolated human placental stem cell that is OCT-4⁺ and CD34⁺, and wherein said placental stem cell is SH3⁺ or SH4⁺.

4. The isolated human placental stem cell of claim 3 wherein said cell is SH3⁺ and SH4⁺.

9. An isolated cell population comprising the human placental stem cells of claim 3.

10. An isolated cell population comprising the human placental stem cells of claim 4.

11. The isolated human placental stem cell of claim 3, wherein the cell has at least one of the following characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SSEA3⁻

, or SSEA4⁻

.

12. The isolated human placental stem cell of claim 4, wherein the cell has at least the following characteristics:

CD10⁺, CD29⁺, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH3⁺, SH4⁺, SSEA3⁻

and SSEA4⁻

.

13. The isolated human placental stem cell of claim 3 wherein said cell is SSEA3⁻

and SSEA4⁻

.

14. An isolated cell population comprising the human placental stem cell of claim 11.

15. An isolated cell population comprising the human placental stem cell of claim 12.

16. An isolated cell population comprising the human placental stem cell of claim 13.

18. The isolated human placental stem cell of claim 4 wherein said cell is SSEA3⁻

and SSEA4⁻

.